SURVYR

REGN

Regeneron Pharmaceuticals, Inc.
$790.74
−$5.60 (0.70%)Oct 16 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-4%+9%+23%+36%+50%Oct 2025Oct 2026Apr 202652w high $859.3452w low $575.93
REGNSPY
Wall St. Highest PT $1,030.00 (+30.3%) Wall St. Avg PT $867.33 (+9.7%)
$566$690$814$937$1,061POC $740Hi $1,030Avg $867
Underwater Drawdown %Max DD -25.9%Current -7.2%
0.0%-25.9%
Relative Strength vs SPY+21.9% vs SPYOutperforming
+43%0%-43%
1W
+$44.20 (5.92%)
1M
+$16.13 (2.08%)
3M
+$114.84 (16.99%)
6M
+$42.16 (5.63%)
YTD
+$21.84 (2.84%)
1Y
+$224.47 (39.64%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
27 analysts · mean score 1.82
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$790.74
Average target$867.33
+$76.59 (+9.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$730.00
Median$867.33
High$1,030.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-21 · TD Cowen reiterated Buy on REGN
Reiterated
2026-10-19 · Piper Sandler reiterated Overweight on REGN
Upgrade
2026-10-15 · UBS upgraded REGN from Neutral to Buy
Reiterated
2026-10-08 · RBC Capital reiterated Sector Perform on REGN
Reiterated
2026-10-07 · Truist Securities reiterated Buy on REGN
Reiterated
2026-10-07 · Morgan Stanley reiterated Equal-Weight on REGN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$82.9B
P/E (last 12 months)19.9
P/E (next 12 months, estimated)12.8
52-week range$575.93 – $859.34
Revenue growth (latest quarter vs a year ago)+16.7%
Dividend yield0.47%
Analyst consensusBuy (27)
Average analyst price target$867.33 (+10%)

What they do

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
48th percentile in sector
C
12-1 return: +16.9%
Percentile within its GICS sector across the S&P 1500.
Growth
75th percentile in sector
B+
Revenue growth (YoY): +16.7%
Percentile within its GICS sector across the S&P 1500.
Value
62nd percentile in sector
B-
Forward E/P: 7.8% · EBITDA/EV: 6.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
75th percentile in sector
B+
Profit margin: +27.9% · Return on equity: +14.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 84 of 499 · 12-month momentum 42.9%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

REGN earningsNext report in 3 days
Next report · quarter Sep 2026
Fri Oct 30, 2026Before the open
EPS consensus$16.19 range $14.88–$17.68
Revenue consensus$4.6B 21 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026$14.29est $10.21+40.0%Above estimates
Apr 29, 2026$9.47est $8.90+6.4%Above estimates
Jan 30, 2026$11.44est $10.75+6.4%Above estimates
Oct 28, 2025$11.83est $9.64+22.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 11:11:18 ET
24-1025-0225-0425-0825-1026-0126-0426-070.0014.29
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$4.3B+16.7%
2026-03-31$3.6B–
2025-12-31$3.9B–
2025-09-30$3.8B–
2025-06-30$3.7B–

Recent dividends

2026-08-18: $0.940 · 2026-05-20: $0.940 · 2026-02-20: $0.940 · 2025-11-20: $0.880 · 2025-08-18: $0.880 · 2025-05-20: $0.880 · 2025-02-20: $0.880

News & catalysts

More news
Has Regeneron Stock Become A Different Bet?
Trefis · 6h ago
Why Should You Think About Vertex Differently Now?
Trefis · Oct 20
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results
Insider Monkey · Oct 19
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Zacks · Oct 19
Rating changes
Reiterated
2026-10-21 · TD Cowen reiterated Buy on REGN
Reiterated
2026-10-19 · Piper Sandler reiterated Overweight on REGN
Upgrade
2026-10-15 · UBS upgraded REGN from Neutral to Buy
Reiterated
2026-10-08 · RBC Capital reiterated Sector Perform on REGN
Reiterated
2026-10-07 · Truist Securities reiterated Buy on REGN
Reiterated
2026-10-07 · Morgan Stanley reiterated Equal-Weight on REGN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 11:11:18 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026